World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
78
Citations
27663
World Ranking
17886
National Ranking
224

Ahmad Awada publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Ahmad Awada sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 712 publications — 82nd percentile

82% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Ahmad Awada D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Ahmad Awada sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 78 D-Index — 12th percentile

12% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Ahmad Awada is affiliated with the Université Libre de Bruxelles in Belgium. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with significant contributions in Oncology, Pulmonary and Respiratory Medicine, and Molecular Biology as key subfields.

The main topics addressed in their research include:

  • Advanced Breast Cancer Therapies
  • Cancer Immunotherapy and Biomarkers
  • Cancer Genomics and Diagnostics
  • Lung Cancer Research Studies
  • Cancer Treatment and Pharmacology
  • HER2/EGFR in Cancer Research
  • Brain Metastases and Treatment

Among the frequent publication venues for Awada's work are:

  • Cancer Research
  • Annals of Oncology
  • Journal of Clinical Oncology
  • ESMO Open
  • Clinical Cancer Research

Co-authors with multiple collaborations include:

  • Nuria Kotecki
  • Evandro de Azambuja
  • Martine Piccart
  • Philippe Aftimos
  • Marianne Paesmans

Recent papers featuring Ahmad Awada encompass:

  • Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial (2020, UNC Libraries)
  • Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial (2020, The Lancet Oncology) [awada is not author]
  • A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer (2020, Clinical Cancer Research) [awada is not author]
  • A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours (2020, British Journal of Cancer) [awada is not author]
  • Humanized Mice as a Valuable Pre-Clinical Model for Cancer Immunotherapy Research (2021, Frontiers in Oncology) [awada is not author]

Ahmad Awada's research shows a focus on clinical trials and cancer treatment methodologies, particularly related to breast cancer therapies and brain metastases. The collaborations and publication venues indicate an active engagement with leading oncology research communities.

Best Publications

  • Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.

    Jan B. Vermorken;Eva Remenar;Carla Van Herpen;Thierry Gorlia

  • Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors

    Dirk Strumberg;Heike Richly;Ralf A. Hilger;Norbert Schleucher

  • Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.

    Sylvia Adams;Peter Schmid;Hope H.S. Rugo;Eric Winer

  • Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

    José Baselga;Seock Ah Im;Hiroji Iwata;Javier Cortés

  • Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer

    Harold J. Burstein;Yan Sun;Luc Y. Dirix;Zefei Jiang

  • Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid Tumors

    Dirk Strumberg;Jeffrey W. Clark;Ahmad Awada;Malcolm J. Moore

  • Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

    Peter A. Kaufman;Ahmad Awada;Chris Twelves;Louise Yelle

  • MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer.

    Stephen Johnston;Miguel Martin;Angelo Di Leo;Seock Ah Im

  • Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer

    Tiffany T.A. Traina;Tiffany T.A. Traina;Kathy Miller;Denise Yardley;Janice Eakle

  • Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

    A Awada;A Hendlisz;T Gil;S Bartholomeus

  • Review: Side Effects of Approved Molecular Targeted Therapies in Solid Cancers

    Christian Widakowich;Christian Widakowich;Gilberto de Castro;Evandro de Azambuja;Evandro de Azambuja;Phuong Dinh

  • Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer

    José Baselga;Patricia Gómez;Richard Greil;Sofia Braga

  • Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial

    Sophie Leboulleux;Lars Bastholt;Thomas Michael Krause;Christelle de la Fouchardiere

  • Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial

    G Gebhart;L. E Lamberts;Z Wimana;C Garcia

  • Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

    José Trigo;Vivek Subbiah;Benjamin Besse;Benjamin Besse;Victor Moreno

  • Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial

    Ahmad Awada;Ramon Colomer;Kenichi Inoue;Igor Bondarenko

  • Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine

    Javier Cortes;Linda Vahdat;Joanne L. Blum;Chris Twelves

  • Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer.

    Lillian L. Siu;Ahmad Awada;Chris H. Takimoto;Martine Piccart

  • Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer

    F Rothé;J-F Laes;Diether Lambrechts;Dominiek Smeets

  • Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies

    Chris C. Twelves;Javier Cortes;Linda L.T. Vahdat;Martin M. Olivo

Frequent Co-Authors

Martine Piccart
Martine Piccart Université Libre de Bruxelles
Javier Cortes
Javier Cortes Vall d'Hebron Hospital Universitari
Marianne Paesmans
Marianne Paesmans Université Libre de Bruxelles
Evandro de Azambuja
Evandro de Azambuja Université Libre de Bruxelles
Fatima Cardoso
Fatima Cardoso Champalimaud Foundation
Véronique Diéras
Véronique Diéras Institute Curie
Hope S. Rugo
Hope S. Rugo University of California, San Francisco
Hans Wildiers
Hans Wildiers KU Leuven
Denis Larsimont
Denis Larsimont Université Libre de Bruxelles
Christos Sotiriou
Christos Sotiriou Université Libre de Bruxelles

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying medicine in the USA opens up diverse career pathways beyond traditional medical practice. Many students consider related online degrees that offer flexibility and affordability. For those interested in advanced nursing, exploring the cheapest DNP program options can help you achieve a doctoral-level qualification at a lower cost.

If you're passionate about pharmaceuticals, attending a pharmacy school online provides a convenient way to earn a PharmD degree without relocating. Alternatively, careers in health administration and data management are growing. Getting an online health information management degree prepares you for roles in medical records, analysis, and information systems.

Entry-level options are also available for those seeking faster pathways into healthcare. Completing a low cost medical coding and billing online program can help you quickly start working in healthcare administration. Each pathway offers its own set of rewards and challenges, so it's important to choose a degree that matches your career goals.

Best Scientists Citing Ahmad Awada

Trending Scientists

Recently Published Articles